Sandbox/AL: Difference between revisions
Line 368: | Line 368: | ||
</div> | </div> | ||
<div class="mw-customtoggle- | <div class="mw-customtoggle-table25" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''''Proteus mirabilis''''' | ▸ '''''Proteus mirabilis''''' | ||
Line 431: | Line 431: | ||
</font> | </font> | ||
</div> | </div> | ||
| valign=top | | | valign=top | | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table12" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table12" style="background: #FFFFFF;" | ||
Line 454: | Line 453: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Daptomycin]] 6 mg IV | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Daptomycin]] 6 mg IV q24h''''' <br> OR <br> ▸ '''''[[Linezolid]] 600 mg IV/PO q12h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from IDSA Guidelines for MRSA<ref name="LiuBayer2011">{{cite journal|last1=Liu|first1=C.|last2=Bayer|first2=A.|last3=Cosgrove|first3=S. E.|last4=Daum|first4=R. S.|last5=Fridkin|first5=S. K.|last6=Gorwitz|first6=R. J.|last7=Kaplan|first7=S. L.|last8=Karchmer|first8=A. W.|last9=Levine|first9=D. P.|last10=Murray|first10=B. E.|last11=Rybak|first11=M. J.|last12=Talan|first12=D. A.|last13=Chambers|first13=H. F.|title=Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children|journal=Clinical Infectious Diseases|volume=52|issue=3|year=2011|pages=e18–e55|issn=1058-4838|doi=10.1093/cid/ciq146}}</ref></SMALL> | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from IDSA Guidelines for MRSA<ref name="LiuBayer2011">{{cite journal|last1=Liu|first1=C.|last2=Bayer|first2=A.|last3=Cosgrove|first3=S. E.|last4=Daum|first4=R. S.|last5=Fridkin|first5=S. K.|last6=Gorwitz|first6=R. J.|last7=Kaplan|first7=S. L.|last8=Karchmer|first8=A. W.|last9=Levine|first9=D. P.|last10=Murray|first10=B. E.|last11=Rybak|first11=M. J.|last12=Talan|first12=D. A.|last13=Chambers|first13=H. F.|title=Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children|journal=Clinical Infectious Diseases|volume=52|issue=3|year=2011|pages=e18–e55|issn=1058-4838|doi=10.1093/cid/ciq146}}</ref></SMALL> | ||
Line 511: | Line 510: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g q12h''''' <br> OR <br> ▸ '''''[[Piperacillin] 3 g q6h'''''<br> OR <br> ▸ '''''[[Imipenem]] 500 q6h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g q12h''''' <br> OR <br> ▸ '''''[[Piperacillin]] 3 g q6h'''''<br> OR <br> ▸ '''''[[Imipenem]] 500 q6h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | ||
Line 553: | Line 552: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Levofloxacin]] 750 mg IV/PO | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Levofloxacin]] 750 mg IV/PO q24h'''''<br> OR <br> ▸ '''''[[Moxifloxacin]] 400 mg IV/PO q24h''''' <BR> OR <BR> ▸ '''''[[Clarithromycin]] 500 mg PO q12h''''' | ||
|- | |- | ||
|} | |} | ||
Line 564: | Line 563: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Intensive Phase | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Intensive Phase | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 5mg/kg PO | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 5mg/kg PO q24h for 2 months'''''<BR> OR <BR> ▸ '''''[[Isoniazid]] 10 mg/kg PO 3 times per week × 2 months''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 10 mg/kg PO | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 10 mg/kg PO q24h for 2 months''''' <BR> OR <BR> ▸ '''''[[Rifampicin]] 10 mg/kg PO 3 times per week × 2 months''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Pyrazinamide]] 25mg/kg PO | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Pyrazinamide]] 25mg/kg PO q24h for 2 months'''''<BR> OR <BR> ▸ '''''[[Pyrazinamide]] 35 mg/kg PO 3 times per week × 2 months''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ethambutol]] 15mg/kg PO | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ethambutol]] 15mg/kg PO q24h for 2 months''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Continuation Phase | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Continuation Phase | ||
Line 584: | Line 583: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 10 mg/kg PO | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 10 mg/kg PO q24h for 4-7 months''''' <BR> OR <BR> ▸ '''''[[Rifampicin]] 10 mg/kg PO 3 times per week for 4-7 months''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Treatment of Tuberculosis: Guidelines.''<ref>{{Cite book | last1 = | first1 = | last2 = | first2 = | title = Treatment of tuberculosis : guidelin | date = 2010 | publisher = World Health Organization | location = Geneva | isbn = 978-92-4-154783-3 | pages = }}</ref></SMALL> | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Treatment of Tuberculosis: Guidelines.''<ref>{{Cite book | last1 = | first1 = | last2 = | first2 = | title = Treatment of tuberculosis : guidelin | date = 2010 | publisher = World Health Organization | location = Geneva | isbn = 978-92-4-154783-3 | pages = }}</ref></SMALL> | ||
Line 601: | Line 600: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Azithromycin]] 500 mg PO | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Azithromycin]] 500 mg PO q24h for 7–10 days''''' <br> OR <br> ▸ '''''[[Clarithromycin]] 500 mg PO q12h for 14–21 days''''' <br> OR <br> ▸ '''''[[Erythromycin]] 500 mg PO q6h for 14–21 days''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from IDSA Guidelines: The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: <ref>{{cite journal|doi=10.1086/522848}}</ref></SMALL> | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from IDSA Guidelines: The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: <ref>{{cite journal|doi=10.1086/522848}}</ref></SMALL> | ||
Line 642: | Line 641: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | FOLLOWED BY | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | FOLLOWED BY | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Trimethoprim/Sulfamethoxazole]] 160mg/800mg PO | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Trimethoprim/Sulfamethoxazole]] 160mg/800mg PO q24h for 1 year''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | ||
Line 650: | Line 649: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | FOLLOWED BY | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | FOLLOWED BY | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Trimethoprim/Sulfamethoxazole]] 160mg/800mg PO | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Trimethoprim/Sulfamethoxazole]] 160mg/800mg PO q24h for 1 year''''' | ||
|- | |- | ||
|} | |} |
Revision as of 19:54, 19 May 2014
The treatment for septic arthritis requires an adequate drainage of purulent joint fluid and appropriate antimicrobial therapy. Empiric therapy should be started after the collection joint fluid and blood sample, and these should be send for culture.
Empiric Therapy Adapted from Lancet 375:846, 2010. [1]
▸ Click on the following categories to expand treatment regimens.
▸ Pediatric ▸ Newborns (< 1 week) ▸ Newborns (1 -4 week) ▸ Infants (1 - 3 months) ▸ Children (3 mo - 14 yr) ▸ Adults ▸ Acute Monoarticular ▸ Chronic Monoarticular ▸ Polyarticular |
|
CSF Gram Stain-Based Therapy Adapted from Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases[2]
▸ Click on the following categories to expand treatment regimens.
Gram-Positive ▸ Gram-Positive Cocci Gram-Negative ▸ Gram-Negative Cocci ▸ Gram-Negative Rods ▸ Negative Gram Stain |
|
Pathogen-Based Therapy — Bacteria Adapted from
▸ Click on the following categories to expand treatment regimens.
Bacteria ▸ E. coli ▸ Enterococcus spp. ▸ Haemophilus influenzae ▸ Neisseria gonorrhoeae ▸ Proteus mirabilis ▸ Pseudomonas aeruginosa ▸ Staphylococcus aureus ▸ Staphylococcus epidermidis ▸ Streptococcus groups A, B, C, G ▸ T. whipplei Mycobacteria ▸ Mycobacterium tuberculosis Spirochetes ▸ Borrelia burgdorferi ▸ Treponema pallidum |
|
Pathogen-Based Therapy — Fungi
▸ Click on the following categories to expand treatment regimens.
Fungi ▸ Candida ▸ Coccidioides ▸ Blastomyces ▸ Histoplasma ▸ Sporothrix ▸ Aspergillus |
|
Pathogen-Based Therapy in Patients with Prosthetic Joint — Bacteria Adapted from Diagnosis and Management of Prosthetic Joint Infection CID 2013:56[7]
▸ Click on the following categories to expand treatment regimens.
Bacteria ▸ Staphylococci, oxacillin-susceptible ▸ Staphylococci, oxacillin-resistant ▸ Enterococcus spp, penicillin-susceptible ▸ Enterococcus spp, penicillin-resistant ▸ Pseudomonas aeruginosa ▸ Enterobacter spp ▸ Enterobacteriaceae ▸ β-hemolytic streptococci ▸ Propionibacterium acnes |
|
- ↑ . doi:10.1016/S0140-6736(09)61595-6. Check
|doi=
value (help). Missing or empty|title=
(help) - ↑ Mandell, Gerald L.; Bennett, John E. (John Eugene); Dolin, Raphael. (2010). Mandell, Douglas, and Bennett's principles and practice of infectious disease. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN [[Special:BookSources/<!DOCTYPE|<!DOCTYPE]] Check
|isbn=
value: invalid character (help). - ↑ Liu, C.; Bayer, A.; Cosgrove, S. E.; Daum, R. S.; Fridkin, S. K.; Gorwitz, R. J.; Kaplan, S. L.; Karchmer, A. W.; Levine, D. P.; Murray, B. E.; Rybak, M. J.; Talan, D. A.; Chambers, H. F. (2011). "Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children". Clinical Infectious Diseases. 52 (3): e18–e55. doi:10.1093/cid/ciq146. ISSN 1058-4838.
- ↑ Treatment of tuberculosis : guidelin. Geneva: World Health Organization. 2010. ISBN 978-92-4-154783-3.
- ↑ . doi:10.1086/522848. Missing or empty
|title=
(help) - ↑ "http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5511a1.htm". Retrieved 19 May 2014. External link in
|title=
(help) - ↑ Osmon, D. R.; Berbari, E. F.; Berendt, A. R.; Lew, D.; Zimmerli, W.; Steckelberg, J. M.; Rao, N.; Hanssen, A.; Wilson, W. R. (2012). "Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases. 56 (1): e1–e25. doi:10.1093/cid/cis803. ISSN 1058-4838.